You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 6, June 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Neuro-otology
 •Balance Disorders
 •Alert me on articles by topic

Effect of Parenteral Aminoglycoside Administration on Dark Cells in the Crista Ampullaris

Sebahattin Cureoglu, MD; Patricia A. Schachern, BS; Michael M. Paparella, MD

Arch Otolaryngol Head Neck Surg. 2003;129:626-628.

Objective  To observe the early and late effects of the parenteral administration of aminoglycosides on the dark cells of ampullae in the inner ear.

Study Design  Comparative study of the histopathologic characteristic of human temporal bones.

Subjects and Methods  Sixty-three temporal bones from 44 subjects (age range, 16-81 years) were examined by light microscopy. Three groups of temporal bones were selected for this study: group 1, 30 "normal" temporal bones from 22 subjects (mean age, 59 years; age range, 25-81 years) with no history or histopathologic findings of otologic disease or ototoxic drug use; group 2, 14 temporal bones from patients who received aminoglycoside treatment within 2 weeks before death; and group 3, 19 temporal bones from patients who received aminoglycoside treatment between 2 weeks and 6 months before death.

Results  The mean ± SD number of dark cells in group 1 was 15.0 ± 2.47; in group 2, it was 17.3 ± 1.93 in the subjects who received gentamicin sulfate and 15.0 ± 3.08 in those who received kanamycin sulfate and tobramycin; in group 3 , it was 14.6 ± 1.67 in the subjects who received gentamicin and 15.2 ± 2.31 in those who received kanamycin and tobramycin. The overall difference between the 3 groups was not statistically significant (P = .07). The cytologic characteristics of dark cells were similar in all 3 groups. The number of dark cells showed a decline with increasing age in group 1.

Conclusions  The result of this study suggests that the treatment period was probably too short to destroy the dark cells. Therefore, long-term aminoglycoside therapy may be necessary to get a more permanent result.


From the Department of Otolaryngology, University of Minnesota (Drs Cureoglu and Paparella and Ms Schachern), the International Hearing Foundation (Dr Cureoglu), and the Minnesota Ear, Head, and Neck Clinic (Dr Paparella), Minneapolis. The authors have no relevant financial interest in this article.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.